Brief: Horizon Therapeutics says Tepezza Approved In Brazil For Treatment Of Active Thyroid Eye Disease
26/06/2023 19:30
June 26 (Reuters) - Horizon Therapeutics PLC HZNP.O :
* TEPEZZA® (TEPROTUMUMAB) APPROVED IN BRAZIL FOR THE
TREATMENT OF
ACTIVE THYROID EYE DISEASE (TED)
Source text for Eikon: ID:nBw98tjRJa
Further company coverage: HZNP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Horizon Therapeutics
See all newsDeals of the day-Mergers and acquisitions
Amgen completes $27.8 bln Horizon deal (updated)
Amgen completes acquisition of Horizon Therapeutics
Brief: Amgen Completes Acquisition Of Horizon Therapeutics PLC
On October 5, Court Sanctioned The Scheme Of Arrangement Under Chapter 1 Of Part 9 Of The Irish Companies Act 2014